Holen Sie sich die Stockscreener-App
111.12
2.33%
2.53
Handel nachbörslich:
111.60
0.48
+0.43%
Schlusskurs vom Vortag:
$108.59
Offen:
$107.76
24-Stunden-Volumen:
4.13M
Relative Volume:
1.68
Marktkapitalisierung:
$24.27B
Einnahmen:
$819.56M
Nettoeinkommen (Verlust:
$-1.18B
KGV:
-19.35
EPS:
-5.7434
Netto-Cashflow:
$-951.64M
1W Leistung:
-5.69%
1M Leistung:
-12.25%
6M Leistung:
-31.59%
1J Leistung:
-27.28%
1-Tages-Spanne:
$105.68
$111.54
1-Wochen-Bereich:
$105.68
$119.32
52-Wochen-Spanne:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
111.12 | 25.73B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2026-03-30 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-23 | Eingeleitet | Roth Capital | Buy |
| 2025-12-19 | Fortgesetzt | Truist | Buy |
| 2025-12-04 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-20 | Eingeleitet | William Blair | Outperform |
| 2025-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Eingeleitet | Jefferies | Buy |
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
Insmed | 10/1/26 - ktnv.com
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback - Zacks Investment Research
3 AI Healthcare Stocks With At Least 8% Revenue Growth - Simply Wall Street
Insmed Price Target Cut to $207.00/Share From $237.00 by Barclays - Moomoo
EMBARC and Insmed plan study to evaluate brensocatib in bronchiectasis - scanx.trade
Net income before discontinued operations of Insmed Incorporated – HAN:IM8N - TradingView
Insmed Incorporated (INSM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insmed Incorporated (INSM) stock price, news, quote and history - uk.finance.yahoo.com
Insmed shares deliver 41.43% annualized return over five years - scanx.trade
Insmed TPIP shows sustained improvement in PAH study - scanx.trade
BMO Capital initiates coverage on Insmed with Outperform rating - scanx.trade
Insmed 15-year return: $1,000 investment grows to $27,361 - scanx.trade
$1000 Invested In Insmed 15 Years Ago Would Be Worth This Much Today - Benzinga
3 Healthcare Stocks Showing Why the Sector Still Has Momentum - MarketBeat
Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients? - Yahoo Finance
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Why Insmed (INSM) Stock Is Down Today - Quiver Quantitative
2 New Jersey companies named top places to work for 2026. Here's where - Asbury Park Press
Goldman Sachs initiates Insmed stock coverage with buy rating, $188 target - Investing.com
Goldman Sachs Maintains Insmed(INSM.US) With Buy Rating, Cuts Target Price to $188 - moomoo.com
Insmed Incorporated (INSM) latest stock news and headlines - Yahoo Finance UK
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce - Zacks Investment Research
Insmed stock price target maintained at $195 by Mizuho on FDA review - Investing.com Canada
Did FDA Priority Review of ARIKAYCE ENCORE Data Just Shift Insmed's (INSM) Investment Narrative? - Yahoo Finance
FDA priority review for Insmed's Arikayce sNDA - thepharmaletter.com
Insmed Says FDA Grants Priority Review to Arikayce Supplemental Filing for MAC Lung Disease - Yahoo Finance
Why is Insmed stock climbing today? By Investing.com - Investing.com Canada
Insmed stock rises on FDA priority review for Arikayce By Investing.com - Investing.com Canada
FDA Grants Priority Review To Insmed's SNDA For Arikayce For Treatment Of Mac Lung Disease With PDUFA Target Action Date Set For January 28, 2027 - TradingView
Insmed receives FDA priority review for ARIKAYCE - grafa.com
FDA grants priority review for Insmed’s ARIKAYCE lung disease drug By Investing.com - Investing.com Canada
INSM Looks 44.7% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
FDA grants Priority Review to Insmed's ARIKAYCE for full approval in treating MAC lung disease - Pluang
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 - Insmed Incorporated Investor Relations
Insmed Incorporated (INSM) Gets FDA Priority Review; PDUFA Jan 28, 2027 - TradingView
A lung-disease drug may reach patients earlier. Insmed gets FDA priority review. - Stock Titan
Insmed stock slips after strong earnings surprise and rich valuation debate - AD HOC NEWS
Insmed Stock Price Forecast. Should You Buy INSM? - StockInvest.us
Insmed Inc (INSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Is Insmed (INSM) Fully Priced After Its 296% Revenue Surge? - webull.com
The Fund Exited Insmed (INSM) After the Investment Thesis Played Out - Yahoo Finance
Insmed Expands Community Impact During Fifth Annual Global Day of Good - PR Newswire
1INSM.MI Interactive Stock Chart | INSMED INC Stock - Yahoo Finance
INSMED Inc Director Brennan David R Sells 25,000 Shares at $124 Each on September 9, 2026 - Kalkine Media
Insmed(INSM.US) Director Sells US$3.1 Million in Common Stock - Moomoo
Insmed Director Sold Shares Worth Over $3.1M - TradingView
Insmed (INSM) director sells 25,000 shares in open-market deal - Stock Titan
Insmed (NASDAQ: INSM) director lines up 25,000-share sale - Stock Titan
Exiting Insmed (INSM) Following Disappointing Key Drug Uptake - Yahoo Finance
Can Insmed (INSM) Still Look Reasonable After Raised Sales Guidance? - webull.com
Insmed Incorporated at Cantor Global Healthcare Conference Transcript - GuruFocus
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):